FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.194,23 -122,86 (-0,21%)
Monte Rosa Therapeutics, Inc. (GLUE)
Dopo ore:
| Chiusura precedente | 5,60 |
| Aperto | 5,82 |
| Denaro | 5,59 x 100 |
| Lettera | 5,69 x 200 |
| Min-Max giorno | 5,64 - 5,85 |
| Intervallo di 52 settimane | 2,44 - 8,84 |
| Volume | |
| Media Volume | 138.727 |
| Capitalizzazione | 284,338M |
| Beta (5 anni mensile) | 1,45 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,63 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,50 |
GlobeNewswireMonte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for MRT-2359 for the treatment of small cell lung cancer (SCLC)Announced development candidate MRT-6160, a novel, highly selective molecular glue degrader of VAV1, with IND submission expected 1H 2024Strong cash position expected to sustain operations into 2025 and enable advancement of p
- GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. ”Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our B
- GlobeNewswire
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to present at the following investor and industry events in June: BIO International Healthcare Conference in Boston; panel entitled “From Serendipity to Rational Design, Redefining the Rules of Molecular Glue Discovery” on June 5 at 1PM ET in Session Room 208Jefferies
